Eisai Announces Preliminary Results of Phase III Study of Halaven® (Eribulin) in Locally Advanced or Metastatic Breast Cancer
Hatfield, England (ots/PRNewswire) - Eisai Europe Limited today announces preliminary results from a recently completed Phase III study (Study 301) comparing Halaven(R) (eribulin) and Xeloda(R) (capecitabine). The study enrolled women with locally advanced or metastatic breast cancer in an earlier line of treatment ...